Aprotinin during coronary artery bypass graft surgery has long-term mortality risks

摘要

Patients given aprotinin,a serine protease inhibitor,to reduce blood loss during coronary artery bypass graft (CABG) surgery are at an in- creased risk of death after five years' follow-up,a study published this week in JAMA suggests (2007;297:471).